Solubility advantage of amorphous pharmaceuticals: II. application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals

Pharmaceutical Research

Volumn 27, Issue 12, 2010, Pages 2704-2714

  Bogner, Robin H ^a,b   Murdande, Sharad B ^a,b   Pikal, Michael J ^a   Shanker, Ravi M ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b PFIZER INC   (United States)

Author keywords

Amorphous; Crystal; Dissolution; Re crystallization; Solubility; Solubility enhancement; Solute activity in amorphous; Thermodynamics

Indexed keywords

DANAZOL; GLIBENCLAMIDE; GLIPIZIDE; GRISEOFULVIN; HYDROCHLOROTHIAZIDE; INDOMETACIN; IOPANOIC ACID; SPIRONOLACTONE; TERFENADINE; WATER;

ANALYTICAL ERROR; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STRUCTURE; GRAVIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IONIZATION; MOISTURE; PH; PHYSICAL CHEMISTRY; POLARIZATION MICROSCOPY; PREDICTION; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; THERMODYNAMICS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MODELS, CHEMICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; THERMODYNAMICS;

EID: 78651288987     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0269-5     Document Type: Article

References (31)

1. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J Pharm Sci. 2010;99:1254-64.
2. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86:1-12.
3. Yu L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:27-42.
4. Craig DQ, Royall PG, Kett VL, Hopton ML. The relevance of the amorphous state to pharmaceutical dosage forms: Glassy drugs and freeze dried systems. Int J Pharm. 1999;179:179-207.
5. Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: Molecular aspects, design and performance. Crit Rev Ther Drug Carr Syst. 2004;21:133-93.
6. Li DX, Oh Y-K, Lim S-J, Kim JO, Yang HJ, Sung JH, et al. Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique. Int J Pharm. 2008;355:277-84.
7. Kim J-S, Kim M-S, Park HJ, Jin S-J, Lee S, Hwang S-J. Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process. Int J Pharm. 2008;359:211-9.
8. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12:1068-75.
9. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res. 2000;17:397-404.
10. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci. 2003;20:305-17.
11. Bansal SS, Kaushal AM, Bansal AK. Molecular and thermodynamic aspects of solubility advantage from solid dispersions. Mol Pharmaceutics. 2007;4:794-802.
12. Ran Y, Neera J, Yalkowsky SH. Solubility and partitioning of aqueous solubility of organic compounds by the General Solubility Equation (GSE). J Chem Inf Comput Sci. 1980;41: 1208-17.
13. Yalkowski SH, Valvani SC. Solubility and partitioning I: Solubility of nonelectrolytes in water. J Pharm Sci. 1980;69:912-22.
14. Neera J, Yalkowsky SH. Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J Pharm Sci. 2001;90:234-52.
15. Yalkowsky SH. Estimation of the aqueous solubility of complex organic compounds. Chemosphere. 1993;26:1239-61.
16. Yalkowsky SH. Solubility and partitioning V: Dependence of solubility on melting point. J Pharm Sci. 1981;70:971-3.
17. Amidon GL, Williams NA. A solubility equation for nonelectrolytes in water. Int J Pharm. 1982;11:249-56.
18. http://www.who.int/medicines/publications/essentialmedicines/ en/. WHO Model List. Essential Medicines. http://www.who. int/medicines/publications/ essentialmedicines/en/.
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3-25.
20. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26. (Pubitemid 33653411)
21. Manderschid M, Eichinger T. Determination of pKa values by liquid chromatography. J Chromatogr Sci. 2003;41:323-6.
22. Murdande SB, Pikal M, Shanker R, Bogner R. Aqueous solubility of crystalline and amorphous drugs: Challenges in measurement. Pharm Dev Technol. (2010). doi:10.3109/10837451003774377.
23. Johari GP, Shanker RM. Calorimetric relaxation and the glassliquid temperature range of acetaminophen-nifedipine alloys. J Pharm Sci. 2007;9999:n/a
24. Tombari E, Presto S, Johari G, Shanker R. Molecular mobility, thermodynamics and stability of Griseofulvin's ultraviscous and glassy states from dynamic heat capacity. Pharm Res. 2008;25: 902-12.
25. Wan H, Holmen AG, Wang Y, Lindberg W, Englund M, Nagard MB, et al. High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry. Rapid Commun Mass Spectrom. 2003;17: 2639-48.
26. Gerakis AM, Koupparis MA, Efstathiou CE. Micellar acid-base potentiometric titrations of weak acidic and/or insoluble drugs. J Pharm Biomed Anal. 1993;11:33-41.
27. Chiang P-C, Foster KA, Whittle MC, Su C-C, Pretzer DK. Medium throughput pKa determinations of drugs and chemicals by reverse phase HPLC with an organic gradient. J Liq Chromatogr Relat Technol. 2006;29:2291-301.
28. Wiczling P, Kawczak P, Nasal A, Kaliszan R. Simultaneous determination of pKa and lipophilicity by gradient RP HPLC. Anal Chem. 2006;78:239-49.
29. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm. 2008;5:927-36.
30. Greco K, Bogner RH. Crystallization of amorphous indomethacin during dissolution: Effect of processing and annealing. Mol Pharm (2010). doi:10.1021/mp1000197.
31. Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility. J Pharm Sci. 2002;91:1863-72.